-
SANOFI-AVENTIS U.S. LLC et al v. BPI LABS, LLC et al DC
- 3:15-cv-02521
- D.N.J.
- Judge: Michael A. Shipp +1
- Filed: 04/06/2015
- Closed: 03/05/2018
- Latest Docket Entry: 03/05/2018
- PACER
- Docket updated daily
3
Plaintiffs
2
Defendants
1
Accused
Product
1
Patent-in-Suit
1,065
Days in
Litigation
-
SANOFI-AVENTIS U.S. LLC et al v. BPI LABS, LLC et al DC
- 3:15-cv-02521
- D.N.J.
- Judge: Michael A. Shipp +1
- Filed: 04/06/2015
- Closed: 03/05/2018
- Latest Docket Entry: 03/05/2018
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
7 |
The method according to claim 1, wherein said cabazitaxel, or hydrate or solvate thereof, is administered in an amount to provide an AUC of about 991 ng·h/mL (CV 34%).
|
Valid (103)
Entry 27 |
11 |
The method according to claim 10, further comprising discontinuing cabazitaxel treatment in a patient with a neutrophil count of ≦1,500 cells/mm<sup>3</sup>.
|
Valid (103)
Entry 27 |
14 |
The method according to claim 13, where the prednisone or prednisolone is administered at a dose of 10 mg/day.
|
Valid (103)
Entry 27 |
15 |
The method according to claim 14, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m<sup>2</sup>.
|
Valid (103)
Entry 27 |
16 |
The method according to claim 14, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 25 mg/m<sup>2</sup>.
|
Valid (103)
Entry 27 |
21 |
The method according to claim 20, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m<sup>2</sup>.
|
Valid (103)
Entry 27 |
26 |
The method according to claim 1, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m<sup>2</sup>.
|
Valid (103)
Entry 27 |
30 |
The method according to claim 27, where the cabazitaxel, or hydrate or solvate thereof, is administered at a dose of 20 mg/m<sup>2</sup>.
|
Valid (103)
Entry 27 |